Efficacy, Safety, and Biomarkers of Toripalimab in Patients with Recurrent or Metastatic Neuroendocrine Neoplasms: A Multiple-Center Phase Ib Trial.

Ming LuChangsong QiZhongwu LiJifang GongJie LiJian LiYan LiZhihao LuXicheng WangJun ZhouZhi PengWeifeng WangHui FengHai WuSheng YaoLin Shen

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Toripalimab had antitumor activity and safety in treating recurrent or metastatic NENs. Patients with positive PD-L1 expression, TMB-H (top 10%), and/or microsatellite instable (MSI-H) might preferentially benefit from the treatment. The genomic mutation of ARID1A and high genomic rearrangements might be correlated with clinical benefit.

Keyphrases

squamous cell carcinoma
small cell lung cancer
copy number
clinical trial
study protocol
phase iii
phase ii
randomized controlled trial
gene expression